Skip to main content

Misty D. Smith

Misty D. Smith, PhD

Research Assistant Professor, Pharmacology and Toxicology

Research Assistant Professor, Pharmacology and Toxicology

Contact: Misty.Smith@pharm.utah.edu

Office: 102A Skaggs Hall

Education:

  • B.S. 1996, Muskingum University
  • Ph.D. 2001, University of South Carolina School of Medicine

FAR Webpage

Research Interests

Dr. Smith is a behavioral pharmacologist whom serves as a co-investigator in the NIH-sponsored Anticonvulsant Drug Development (ADD) Program in the Department of Pharmacology and Toxicology in the College of Pharmacy. Dr. Smith's current research is investigating the therapeutic potential of novel compounds, such as cannabidiol, for the treatment of epilepsy and its comorbidities and characterizing the drug interactions of cannabidiol with other concomitant therapeutics. Additional related research interests include the pharmacotherapeutic potential of neuropeptides, endocannabinoids and other novel therapeutics in the treatment of chronic pain, substance abuse and other neuropsychiatric conditions. Dr. Smith also has a joint appointment as a career-track (research) Assistant Professor in the Oral Biology, Medicine, and Pathology Section of the School of Dentistry at the University of Utah.

Publications

    • Smith MD, Woodhead JH, Handy LS, Pruess TH, Vanegas F, Grussendorf E, Grussendorf J, White K, Bulaj K, Krumin RK, Hunt M, Wilcox KS. Preclinical Comparison of Mechanistically Different Antiseizure, Antinociceptive and/or Antidepressant Drugs in a Battery of Rodent Models of Nociceptive and Neuropathic Pain. Neurochem. Res. 2017 May 15. DOI 10.1007/s11064-017-2286-9 [Epub ahead of print] PMID 28508174
    • Lin Z, Smith MD, Concepcion GP, Haygood MG, Olivera BM, Light A, Schmidt EW. Modulating the Serotonin Receptor Spectrum of Pulicatin Natural Products. J Nat Prod. 2017 Jul 26. doi: 10.1021/acs.jnatprod.7b00317. [Epub ahead of print] PubMed PMID: 28745513.
    • Klein BD, Jacobsen CA, Metcalf CS, Smith MD, Wilcox KS, Hampson AJ, Kehne JH. Evaluation of Cannabidiol in animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP). Neurochem. Res. 2017 May 6. DOI: 10.1007/s11064-017-2287-8 [Epub ahead of print] PMID: 28478594
    • Metcalf CS, West PJ, Thomson KE, Edwards SF, Smith MD, White HS, Wilcox KS. Development and pharmacological characterization of the rat 6Hz model of partial seizures. Epilepsia. 2017 Apr 27. DOI:10.1111/epi.13764 [Epub ahead of print] PMID 28449218
    • Metcalf CS, Smith MD, Klein BD, McDougle DR, Zhang L, Bulaj G. Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2. Neurochem Res. 2017 Apr 6. DOI 10.1007/s11064-017-2229-5 [Epub ahead of print] PMID: 28382595
    • Metcalf CS, Klein BD, Smith MD, Pruess T, Ceusters M, Lavreysen H, Pype S, Van Osselaer N, Twyman R, White HS. Efficacy of mGlu2 -positive allosteric modulators alone and in combination with levetiracetam in the mouse 6 Hz model of psychomotor seizures. Epilepsia. 2017 Mar;58(3):484-493. DOI: 10.1111/epi.13659. PMID: 28166368
    • Barker-Haliski ML, Johnson K, Billingsley P, Huff J, Handy LJ, Khaleel R, Lu Z, Mau MJ, Pruess TH, Rueda C, Saunders G, Underwood TK, Vanegas F, Smith MD, West PJ, Wilcox KS. Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy. Neurochem Res. 2017 Mar 16. DOI: 10.1007/s11064-017-2227-7. [Epub ahead of print] PMID: 28303498
    • Kaufmann D, West PJ, Smith MD, Yagen B, Bialer M, Devor M, White HS, Brennan KC. sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. Pharmacol Res. 2017 Mar;117:129-139. DOI: 10.1016/j.phrs.2016.11.030. PMID: 27890817
    • Pittenger ST, Swalve N, Chou S, Smith MD, Hoonakker AJ, Pudiak CM, Fleckenstein AE, Hanson GR, Bevins RA. Sex differences in neurotensin and substance P following nicotine self-administration in rats. Synapse. 2016 Apr 13. DOI: 10.1002/syn.21907. PMID: 27074301 [Epub ahead of print]
    • Vieira-Brock PL, McFadden LM, Nielsen SM, Smith MD, Hanson GR, Fleckenstein AE. Nicotine Administration Attenuates Methamphetamine-Induced Novel Object Recognition Deficits. Int J Neuropsychopharmacol. 2015 Jul 11;18(12). pii: pyv073. DOI: 10.1093/ijnp/pyv073. PMID: 26164716
    • Lee HK, Zhang L, Smith MD, Walewska A, Vellore N, Baron R, McIntosh JM, White HS, Olivera BM, Bulaj G. A Marine Analgesic Peptide, Contulakin-G, and Neurotensin Receptors: Uncovering Structural Determinants of Desensitization Properties. Front Pharmacol. 2015 Feb 10. 6:11.DOI 10.3389/fphar.2015.0011
    • Metcalf CS, Klein BD, McDougle DR, Zhang L, Smith MD, Bulaj G, White HS. Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models. J Pharmacol Exp Ther. 2015 Jan;352(1):185-93. PMCID: PMC4279104.
    • Umpierre AD, Remigio GJ, Dahle EJ, Bradford K, Alex AB, Smith MD, West PJ, White HS, Wilcox KS. Impaired cognitive ability and anxiety-like behavior following acute seizures in the Theiler’s virus model of temporal lobe epilepsy. Neurobiol Dis. 2014 Jan 9.PMID 24412221
    • Green BR, Klein BD, Lee H-K, Smith MD, White, HS, Bulaj G. Cyclic analogs of galanin and neuropeptide Y by hydrocarbon stapling. Bioorganic & Medicinal Chemistry. 2013. 21 (1) 303-310.
    • Zhang L, Klein BD, Metcalf CS, Smith MD, McDougle DR, Lee HK, White HS, Bulaj G. Incorporation of Monodisperse Oligoethyleneglycol Amino Acids into Anticonvulsant Analogs of Galanin and Neuropeptide Y Provides Peripherally-Acting Analgesics. Mol Pharm. 2013; 10(2):574-85.
    • Gowd KH, Han TS, Twede V, Gajewiak J, Smith MD, Watkins M, Platt RJ, Toledo G, White HS, Olivera BM, Bulaj G. Conantokins Derived from the Asprella Clade Impart conR1-B, an N-Methyl d-Aspartate Receptor Antagonist with a Unique Selectivity Profile for NR2B Subunits. Biochemistry. 2012. 51(23):4685-92. PMID: 2259448
    • Platt RJ, Han TS, Green BR, Smith MD, Skalicky J, Gruszczynski P, White HS, Olivera B, Bulaj G, Gajewiak J. Stapling mimics noncovalent interactions of gamma-carboxyglutamates in conantokins, peptidic antagonists of N-methyl-D-aspartic acid receptors: J Biol Chem. 2012 Jun 8; 287 (24): 20727-36. Epub 2012 Apr 19. PMID: 22518838.
    • Green BR, Smith MD, White KL, White HS, Bulaj G. Analgesic Neuropeptide W Suppresses Seizures in the Brain Revealed by Rational Repositioning and Peptide Engineering. ACS Chem Neurosci. 2011 Jan 19; 2(1): 51-56.
    • Rowley NM, Smith MD, White HS. Hippocampal Betaine/GABA Transporter mRNA Expression is not Regulated by Inflammation or Dehydration post-Status Epilepticus. J. of Neurochem. 2011 Apr;117(1):82-90.
    •  Green BR, Smith M, White KL, White HS, Bulaj G. Analgesic Neuropeptide W Suppresses Seizures in the Brain Revealed by Rationale Repositioning and Peptide Engineering. ACS Chem. Neurosci., 2011, 2 (1), pp 51-56.
    • Green BR, Smith M, White KL, White HS, Bulaj G. Analgesic Neuropeptide W Suppresses Seizures in the Brain Revealed by Rationale Repositioning and Peptide Engineering. ACS Chem. Neurosci., 2011, 2 (1), pp 51-56.
    • Smith MD, Lee HK, Smith BJ, Grussendorf J, Xu L, Gillies RJ, White HS, Bulaj G. Anticonvulsant Met-enkephalin analogues containing backbone spacers reveal alternative non-opioid signaling in the brain. ACS Chem Biol. 2009 Aug 21;4 (8):659-71.
    • Lee HK, Zhang L, Smith MD, White HS, Bulaj G. Glycosylated neurotensin analogues exhibit sub-picomolar anticonvulsant potency in a pharmacoresistant model of epilepsy. ChemMedChem. 2009 Mar 4(3): 400-5.
    • White HS, Smith MD. Neurotransmitters and Drug Development in Epilepsy. In Advanced Therapy in Epilepsy. Eds. James W. Wheless, L. James Willmore, and Roger A. Brumback. Sheltoon, Connecticut. People's Medical Publishing House. 2009
    • Bulaj G, Green BR, Lee HK, Robertson, CR, White K, Zhang L, Sochanska M, Flynn SP, Scholl EA, Pruess TH, Smith MD, White HS. Design, synthesis, and characterization of high-affinity, systemically active galanin analogues with potent anticonvulsant activities. J Med Chem. 2008 Dec 25; 51(24): 8038-47.
    • Smith, M.D., Saunders G.W., Wilcox, K.S., Clausen, R.P., Frolund, B., Krogsgaard-Larsen, P., Larsson, O.M., Schousboe, A., .and White, H.S. Inhibition of the betaine-GABA transporter (mGAT2/BGT-1) modulates spontaneous electrographic bursting in the medial entorhinal cortex (mEC). Epilepsy Res. 2008 Mar; 79(1):6-13. [Epub 2008 Feb 8.]
    • Smith, M.D., Adams, A.C., Saunders, G.W., White, H.S. and Wilcox K.S. Phenytoin- and Carbamazepine-Resistant Spontaneous Bursting in Rat Entorhinal Cortex Is Blocked by Retigabine In vitro. Epilepsy Res 2007 May; 74(2-3): 97-106. [Epub 2007 Mar 28.]
    • Smith, MD, Wilcox, KS and White, HS. Discovery of Antiepileptic Drugs. Neurotherapeutics. 4(1): 12-17. Jan 2007. PMID: 17199014
    • White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007; 81:85-110. Review.
    • Lenkowski, PW Batts, T.W., Smith, MD, Ko SH, Jones, PJ, Taylor, CH, McCusker, AK, Davis, GC, Hartmann, HA, White, HS, Brown, ML, and Patel, MK. A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile. Neuropharmacology. 2007 Mar; 52(3): 1044-54. [Epub 2006 Dec 14.]
    • Jones, PJ, Wang, Y, Smith, MD, Hargus, NJ, Eidam, HS, White, HS, Kapur, J, Brown, ML, and Patel, MK. Hydroxyamide analogues of propofol exhibit state-dependent block of sodium channels in hippocampal neurons: implications for anticonvulsant activity. J. Pharmacologol Exp Ther. 2007 Feb; 320(2): 828-36. [Epub 2006. Nov. 7.]
    • Eyal, S. Lamb, J.G., Smith-Yockman, M., Yagen, B., Fibach, E., Altschuler, A., White, H.S., and Bialer, M. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br. J of Pharmacol. 2006 Oct;149 (3):250-60. [Epub ahead of print, 2006 Aug 7].
    •  White, HS, Smith-Yockman, M., Srivastava, A. and Wilcox, K.S. Therapeutic Assays for the Identification and Characterization of Antiepileptic and Antiepileptogenic Drugs. In Models of Seizures and Epilepsy. Ed. A. Pitkanen, P.A. Schwartzkroin, and S.L. Moshe. pp.539-549. New York: Elsevier Acad. Press. 2006.

     

    Book Chapters:

    • Smith MD, CS Metcalf, KS White. Chapter 17, Pharmacotherapy of the Epilepsies. In Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th edition, Eds. Brunton, L. L., Knollmann, B. C. & Hilal-Dandan R. (2017). Goodman & Gilman's pharmacological basis of therapeutics. New York: McGraw-Hill.
    • White HS, Smith MD. Neurotransmitters and Drug Development in Epilepsy. In Advanced Therapy in Epilepsy. Eds. James W. Wheless, L. James Willmore, and Roger A. Brumback. (2009) Sheltoon, Connecticut. People's Medical Publishing House.
    • Smith, MD, Wilcox, KS and White, HS. Discovery of Antiepileptic Drugs. Neurotherapeutics. 4(1): 12-17. Jan 2007.
    • White, HS, Smith-Yockman, M., Srivastava, A. and Wilcox, K.S. Therapeutic Assays for the Identification and Characterization of Antiepileptic and Antiepileptogenic Drugs. 2006. In Models of Seizures and Epilepsy. Ed. A. Pitkanen, P.A. Schwartzkroin, and S.L. Moshe. pp.539-549. New York: Elsevier Acad. Press.